Boston Scientific Corporation $BSX Stock Acquired by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. raised its position in Boston Scientific Corporation (NYSE:BSX) by 31.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,596,301 shares of the medical equipment provider’s stock after purchasing an additional 386,008 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Boston Scientific were worth $69,766,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BSX. Perigon Wealth Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at approximately $883,000. Y Intercept Hong Kong Ltd boosted its position in Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after buying an additional 670,060 shares during the period. Wealthfront Advisers LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in Boston Scientific during the 2nd quarter worth approximately $38,539,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock opened at $44.22 on Friday. The stock has a market capitalization of $64.10 billion, a PE ratio of 18.74, a PEG ratio of 1.34 and a beta of 0.60. The business’s 50 day simple moving average is $44.05 and its 200 day simple moving average is $54.75. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $105.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on BSX. Oppenheimer downgraded shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Leerink Partners cut their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Deutsche Bank set a $48.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, October 29th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Finally, Piper Sandler lowered their target price on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $61.43.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.